🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are increasing globally, with figures suggesting over 82 million infections per year. Particularly high rates are seen in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This drug, which is employed against UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

Based on results detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which involves two antibiotics. The trial enrolled hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in many regions with limited resources.

Medical professionals treating patients have shared optimism. Having a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.